SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McGorry PD, Yung AR, Phillips LJ. The ‘close-in’ or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr. Bull. 2003; 29: 771790.
  • 2
    Ruhrmann S, Bechdolf A, Kuhn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br. J. Psychiatry Suppl. 2007; 51: s88s95.
  • 3
    Woods SW, Tully EM, Walsh BC et al. Aripiprazole in the treatment of the psychosis prodrome: An open-label pilot study. Br. J. Psychiatry Suppl. 2007; 51: s96s101.
  • 4
    McGlashan TH, Zipursky RB, Perkins D et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr. Res. 2003; 61: 718.
  • 5
    Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: Treatment and high-risk perspectives. Schizophr. Res. 2002; 54: 177186.
  • 6
    McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002; 59: 921928.
  • 7
    Woods SW, Breier A, Zipursky RB et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry 2003; 54: 453464.
  • 8
    Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: Ethical implications for clinical practice and future research. Schizophr. Bull. 2006; 32: 166178.
  • 9
    Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001; 50: 884897.
  • 10
    Yung AR, Nelson B, Stanford C et al. Validation of ‘prodromal’ criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr. Res. 2008; 105: 1017.
  • 11
    Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr. Bull. 2007; 33: 673681.
  • 12
    Howes OD, Montgomery AJ, Asselin MC et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009; 66: 1320.
  • 13
    Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III – the final common pathway. Schizophr. Bull. 2009; 35: 549562.
  • 14
    Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 2005; 79: 5968.
  • 15
    Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M. Aripiprazole: Effectiveness and safety under naturalistic conditions. Exp. Clin. Psychopharmacol. 2007; 15: 569575.
  • 16
    Gibson AP, Crismon ML, Mican LM, Fischer C. Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: A retrospective evaluation. Int. Clin. Psychopharmacol. 2007; 22: 101105.
  • 17
    Liu CC, Hwu HG, Chiu YN, Lai MC, Tseng HH. Creating a platform to bridge service and research for early psychosis. J. Formos. Med. Assoc. (in press).
  • 18
    Bharadwaj B, Bhargavaraman RP, Ravi PR, Math SB. Aripiprazole in prodromal psychosis: A case report. Prim. Care Companion J. Clin. Psychiatry 2008; 10: 162.
  • 19
    Kobayashi H, Morita K, Takeshi K et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J. Clin. Psychopharmacol. 2009; 29: 421425.
  • 20
    Chan HY, Lin WW, Lin SK et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. J. Clin. Psychiatry 2007; 68: 2936.
  • 21
    Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch. Gen. Psychiatry 2003; 60: 12281235.
  • 22
    Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 2005; 162: 939946.
  • 23
    Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. Br. J. Psychiatry 2004; 185: 291297.
  • 24
    Kessler RM. Aripiprazole: What is the role of dopamine D(2) receptor partial agonism? Am. J. Psychiatry 2007; 164: 13101312.
  • 25
    Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry 2005; 162: 19841985.